← Leaderboards
Daniel Garrett Kavanagh
Massachusetts General Hospital
$1,521,087
Attributed
$1,521,087
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $438.8K · FY2005–18$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$1,521,087 · 4
By mechanism
R21$470,025 · 1
P30$463,040 · 1
R56$438,750 · 1
F32$149,272 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Sylvie Le Gall$9,769,555
- Todd M Allen$28,600,717
- William F Crowley$27,565,527
- Andrew T Chan$39,910,857
- Athe M. Tsibris$17,945,517
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsFlexibilityInnovationDesignAcquired Immunodeficiency SyndromeInfectionCommunitiesEpidemicEquipmentCellular ImagingConsultationsAfricaCollaborationsCommunicable DiseasesCaribbean RegionCertificationAreaBiologyAsiaAnimal FacilityBostonCell SeparationAnimalsContainment
Grant awards (11)
Biosafety Level 3 Core$63,416
P30 · FY2018 · AI · contact PI
Biosafety Level 3 Core$88,127
P30 · FY2017 · AI · contact PI
Biosafety Level 3 Core$102,515
P30 · FY2016 · AI · contact PI
Biosafety Level 3 Core$104,690
P30 · FY2015 · AI · contact PI
Biosafety Level 3 Core$104,292
P30 · FY2014 · AI · contact PI
HLA restriction and TCR affinity in HIV$438,750
R56 · FY2011 · AI · contact PI
Development of needle-free, vectorless, RNA-based vaccines for HIV$254,460
R21 · FY2010 · AI · contact PI
Development of needle-free, vectorless, RNA-based vaccines for HIV$215,565
R21 · FY2009 · AI · contact PI
The T cell response to rapidly evolving HIV antigens$52,048
F32 · FY2006 · AI · contact PI
The T cell response to rapidly evolving HIV antigens$49,928
F32 · FY2005 · AI
The T cell response to rapidly evolving HIV antigens$47,296
F32 · FY2004 · AI